Gene therapy trial aims to halt vision loss in dry AMD

This study tests a new gene therapy called BS01 for people with geographic atrophy, a severe form of dry age-related macular degeneration that causes blind spots. The treatment uses a harmless virus to deliver a light-sensitive protein to the eye, aiming to restore or preserve vision. The trial involves 40 adults aged 50-85 and will first check safety, then measure if it improves eyesight compared to a sham procedure.